ReviewClinical and experimental immunology2004
Immunopathogenic mechanisms in psoriasis.
Review in Clinical and experimental immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis.Clinical drug investigation · 2026Pooled it
- Trial
- Distinct immunological signatures in autoimmunity: a multi-plex analysis for the differential diagnosis of established and undifferentiated autoimmune diseases (a cross-sectional pilot study).Rheumatology international · 2026Article
- High-dimensional single-cell analyses reveal neutrophil heterogeneity in guttate psoriasis.EBioMedicine · 2026Article
- What drives patient cost variability in psoriasis care: a single centre study.BMC health services research · 2025Article
- Salivary Interleukins as Non-Invasive Biomarkers for Psoriasis: Advances and Challenges in Diagnosis and Monitoring.Medicina (Kaunas, Lithuania) · 2025Review
- The Synergetic Effect of Periodontal Therapy and TNF-α Inhibitor for the Treatment of Comorbid Periodontitis and Psoriasis.Journal of clinical periodontology · 2025Article
- Topical delivery of pterostilbene nanoemulgel ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.Nanomedicine (London, England) · 2025Article
- Efficacy of Aster chinensis aerial parts metabolites in BALB/c mice model of Imiquimod-induced psoriasis skin inflammation.Inflammopharmacology · 2025Article
- Vulgar Psoriasis Triggered by Active Pulmonary Tuberculosis: A Case Report and Literature Review Highlighting Immunological Interactions and Genetic Susceptibility.Clinics and practice · 2025Article
- Techniques and analytic workflow for spatial transcriptomics and its application to allergy and inflammation.The Journal of allergy and clinical immunology · 2025Review
- Reduction of Serum Interleukin-17 and Interleukin-23 Levels Following Narrow Band Ultraviolet B Treatment in Patients with Moderate-to-severe Psoriasis Vulgaris.Materia socio-medica · 2025Article
- Comprehensive analysis of pyroptosis-related genes in psoriasis and targeted gene editing of CASP1 and CASP5 using lipid nanoparticles to alleviate skin inflammation.Frontiers in bioengineering and biotechnology · 2025Article
- Diterpenoids with Potent Anti-Psoriasis Activity fromMolecules (Basel, Switzerland) · 2024Article
- Article
- Burden of psoriasis in young adults worldwide from the global burden of disease study 2019.Frontiers in endocrinology · 2024Article
- Efficacy Evaluation of Treatment of Psoriasis Via Narrow Band-Ultraviolet Radiation.Journal of lasers in medical sciences · 2024Article
- An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.Current drug targets · 2024Review
- Mechanistic Investigation of WWOX Function in NF-kB-Induced Skin Inflammation in Psoriasis.International journal of molecular sciences · 2023Article
- Emerging trends in combination strategies with phototherapy in advanced psoriasis management.Inflammopharmacology · 2023Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a common autoimmune skin disease characterized by T cell-mediated hyperproliferation of keratinocytes. The disease has a strong but complex genetic background with a concordance of approximately 60% in monozygotic twins, and recent linkage and high resolution association studies indicate that HLA-Cw*0602 is itself a major susceptibility allele for psoriasis. Patients carrying this allele have been shown to have different clinical features and earlier age of disease onset, and patients homozygous for this allele have about 2.5 times higher disease risk than heterozygotes. Published data indicate that CD8+ T cells may play a major effector role in psoriasis. Epidermal infiltration of predominantly oligoclonal CD8+ T cells, and probably also of CD4+ T cells in the dermis, is a striking feature of chronic psoriasis lesions, indicating that these cells are responding to specific antigens. We argue that CD4+ T cells are essential for initiating and maintaining the pathogenic process of psoriasis but that cross-primed CD8+ T cells are the main effector cells responding to antigens in the HLA-Cw*0602 binding pocket of keratinocytes. It is further proposed that CD8+ T cells are involved in the control of the Th1 polarization, which is observed in psoriasis lesions, through a complex interplay between CD4+, CD8+ T cells and cross-presenting dendritic cells. It is also suggested that spontaneous remissions or fluctuations in disease activity may be determined by a balance within the lesions between effector and suppressor CD4+ and CD8+ T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.